These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 19406184)

  • 1. Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009.
    Hayden FG; Howard WA; Palkonyay L; Kieny MP
    Vaccine; 2009 Jun; 27(31):4079-89. PubMed ID: 19406184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010.
    Girard MP; Katz J; Pervikov Y; Palkonyay L; Kieny MP
    Vaccine; 2010 Oct; 28(42):6811-20. PubMed ID: 20659520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Report of the 4th meeting on the "Evaluation of pandemic influenza prototype vaccines in clinical trials." World Health Organization, Geneva, Switzerland, 14-15 February 2008.
    Girard M; Palkonyay L; Kieny MP
    Vaccine; 2008 Sep; 26(39):4975-7. PubMed ID: 18514979
    [No Abstract]   [Full Text] [Related]  

  • 4. Report of the 7th meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, World Health Organization, Geneva, 17-18 February 2011.
    Girard MP; Katz JM; Pervikov Y; Hombach J; Tam JS
    Vaccine; 2011 Oct; 29(44):7579-86. PubMed ID: 21856358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Report of the fourth meeting on 'Influenza vaccines that induce broad spectrum and long-lasting immune responses', World Health Organization and Wellcome Trust, London, United Kingdom, 9-10 November 2009.
    Stephenson I; Hayden F; Osterhaus A; Howard W; Pervikov Y; Palkonyay L; Kieny MP
    Vaccine; 2010 May; 28(23):3875-82. PubMed ID: 20398616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza A (H5N1) pandemic prototype vaccine Fluval.
    Vajo Z
    Expert Rev Vaccines; 2009 May; 8(5):619-24. PubMed ID: 19397418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NEW technologies for meeting the global demand for pandemic influenza vaccines.
    Fedson DS
    Biologicals; 2008 Nov; 36(6):346-9. PubMed ID: 18715803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5-7 May 2014.
    Cox NJ; Hickling J; Jones R; Rimmelzwaan GF; Lambert LC; Boslego J; Rudenko L; Yeolekar L; Robertson JS; Hombach J; Ortiz JR
    Vaccine; 2015 Nov; 33(48):6503-10. PubMed ID: 26478203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms.
    Luke CJ; Subbarao K
    Expert Rev Vaccines; 2014 Jul; 13(7):873-83. PubMed ID: 24855993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control.
    Kreijtz JH; Osterhaus AD; Rimmelzwaan GF
    Hum Vaccin; 2009 Mar; 5(3):126-35. PubMed ID: 18948744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing vaccines for pandemic influenza.
    Horimoto T; Kawaoka Y
    Curr Top Microbiol Immunol; 2009; 333():165-76. PubMed ID: 19768405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Live attenuated vaccines for pandemic influenza.
    Chen GL; Subbarao K
    Curr Top Microbiol Immunol; 2009; 333():109-32. PubMed ID: 19768402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Report of the third meeting on "influenza vaccines that induce broad spectrum and long-lasting immune responses", World Health Organization, Geneva, Switzerland, 3-4 December 2007.
    Girard MP; Osterhaus A; Pervikov Y; Palkonyay L; Kieny MP
    Vaccine; 2008 May; 26(20):2443-50. PubMed ID: 18420316
    [No Abstract]   [Full Text] [Related]  

  • 14. Pandemic H5N1 influenza vaccine development: an update.
    El Sahly HM; Keitel WA
    Expert Rev Vaccines; 2008 Mar; 7(2):241-7. PubMed ID: 18324892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status and progress of prepandemic and pandemic influenza vaccine development.
    Leroux-Roels I; Leroux-Roels G
    Expert Rev Vaccines; 2009 Apr; 8(4):401-23. PubMed ID: 19348557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
    Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
    Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of live-attenuated influenza vaccines against outbreaks of H5N1 influenza.
    Zheng D; Yi Y; Chen Z
    Viruses; 2012 Dec; 4(12):3589-605. PubMed ID: 23223214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress with human H5N1 vaccines: a perspective from industry.
    Palache B; Krause R
    Expert Rev Vaccines; 2009 Apr; 8(4):391-400. PubMed ID: 19348556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: Process challenges and success stories.
    Rudenko L; Yeolekar L; Kiseleva I; Isakova-Sivak I
    Vaccine; 2016 Oct; 34(45):5436-5441. PubMed ID: 27593158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.